Overview

Double-masked Controlled Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the safety and tolerability and ocular efficacy of SY-201 Ophthalmic Solution versus vehicle over a 60-day treatment period in subjects with dry eye disease (DED).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Seinda Pharmaceutical Guangzhou Corporation
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions